Medigene announces participation at six upcoming investor and scientific conferences
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at six upcoming investor and scientifi…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at six upcoming investor and scientifi…
Die Medigene AG (FWB: MDG1, Prime Standard, TecDAX) gibt ihre Teilnahme an sechs bevorstehenden Investoren- und Wissensc…
- Synergies between the recombinant T cell technologies of Medigene and self-delivering RNAi technologies from RXi Pharm…
Monetization of last remaining legacy product essentially completes Medigene's transformation into a pure-play, clinical…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX), will demonstrate the use of its automated high-throughput screening (HT…
- Automated in vitro testing could reveal better neoantigens that activate more effective killer T cell responses - Two…
. - Automatisiertes in vitro Testverfahren könnte bessere Neoantigene zur Aktivierung von mehr Killer-T-Zellen auffinden…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced the appointment of eight leading experts to its new immu…
Growing revenues from core business immunotherapies, clinical trial application for second immunotherapy submitted, fina…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX), today announced details on the Company's first clinical trial with T-ce…